Goldman Sachs’s Ironwood Pharmaceuticals IRWD Stock Holding History

Goldman Sachs’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-150,086	Closed	-$1.94M	–	5825
2018 Q1	$1.94M	Hold	150,086	–	–	﹤0.01%	3626
2017 Q4	$1.88M	Buy	+150,086	New	+$1.96M	﹤0.01%	3847
2016 Q1	–	Sell	-82,267	Closed	-$799K	–	7191
2015 Q4	$799K	Sell	82,267 -37,133	-31%	-$359K	﹤0.01%	4506
2015 Q3	$1.04M	Buy	119,400 +1,194	+1%	+$11.1K	﹤0.01%	4438
2015 Q2	$1.19M	Buy	+118,206	New	+$1.37M	﹤0.01%	4373
2014 Q1	–	Sell	-119,400	Closed	-$1.16M	–	6841
2013 Q4	$1.16M	Sell	119,400 -119,400	-50%	-$1.07M	﹤0.01%	4595
2013 Q3	$2.37M	Sell	238,800 -71,640	-23%	-$703K	﹤0.01%	3756
2013 Q2	$2.58M	Buy	+310,440	New	+$3.76M	﹤0.01%	3454

Other funds holding IRWD

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's IRWD Position: Q1 2026 in Review

Goldman Sachs increased its Ironwood Pharmaceuticals (IRWD) stake by 111% in Q1 2026, buying an estimated $5.8M and bringing the position to 2,690,634 shares worth $9.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3119.

Goldman Sachs first reported a position in IRWD in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.2M in Q3 2021. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

Goldman Sachs held 2,690,634 shares of Ironwood Pharmaceuticals worth $9.44M as of Q1 2026.
Goldman Sachs bought 1,415,319 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $5.8M.
Ironwood Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3119 holding.
Goldman Sachs first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Ironwood Pharmaceuticals position peaked at $40.2M in Q3 2021.
226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.